KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

SPOTlight on GLOW.

Sarah Derks, Hanneke W M van Laarhoven

Cell Rep Med 4(10) 101233

PMID37852180
PMCIDPMC10591046
DOI10.1016/j.xcrm.2023.101233
发表日期2023-10-18
入排依据:The record describes a Phase 3 randomized trial in human oncology with a drug intervention. However, the provided abstract and metadata do not explicitly mention a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio. Therefore, the time-to-event criterion is not met.
摘要

摘要

The GLOW randomized double-blind phase 3 trial1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。